Notice of Lodging of Proposed Stipulation and Settlement Under the Comprehensive Environmental Response, Compensation and Liability Act, 68523-68524 [2021-26171]
Download as PDF
<![CDATA[
68523
Federal Register / Vol. 86, No. 229 / Thursday, December 2, 2021 / Notices
Established
2022 quotas
(g)
Basic class
Hydromorphone .............................................................................................................................................................................
Isomethadone ................................................................................................................................................................................
L-amphetamine ..............................................................................................................................................................................
Levo-alphacetylmethadol (LAAM) ..................................................................................................................................................
Levomethorphan ............................................................................................................................................................................
Levorphanol ...................................................................................................................................................................................
Lisdexamfetamine ..........................................................................................................................................................................
Meperidine .....................................................................................................................................................................................
Meperidine Intermediate-A ............................................................................................................................................................
Meperidine Intermediate-B ............................................................................................................................................................
Meperidine Intermediate-C ............................................................................................................................................................
Metazocine .....................................................................................................................................................................................
Methadone (for sale) .....................................................................................................................................................................
Methadone Intermediate ................................................................................................................................................................
Methamphetamine .........................................................................................................................................................................
d-methamphetamine (for conversion) ............................................................................................................................................
d-methamphetamine (for sale) ......................................................................................................................................................
l-methamphetamine .......................................................................................................................................................................
Methylphenidate (for sale) .............................................................................................................................................................
Methylphenidate (for conversion) ..................................................................................................................................................
Metopon .........................................................................................................................................................................................
Moramide-intermediate ..................................................................................................................................................................
Morphine (for conversion) ..............................................................................................................................................................
Morphine (for sale) ........................................................................................................................................................................
Nabilone .........................................................................................................................................................................................
Norfentanyl .....................................................................................................................................................................................
Noroxymorphone (for conversion) .................................................................................................................................................
Noroxymorphone (for sale) ............................................................................................................................................................
Oliceridine ......................................................................................................................................................................................
Opium (powder) .............................................................................................................................................................................
Opium (tincture) .............................................................................................................................................................................
Oripavine ........................................................................................................................................................................................
Oxycodone (for conversion) ..........................................................................................................................................................
Oxycodone (for sale) .....................................................................................................................................................................
Oxymorphone (for conversion) ......................................................................................................................................................
Oxymorphone (for sale) .................................................................................................................................................................
Pentobarbital ..................................................................................................................................................................................
Phenazocine ..................................................................................................................................................................................
Phencyclidine .................................................................................................................................................................................
Phenmetrazine ...............................................................................................................................................................................
Phenylacetone ...............................................................................................................................................................................
Piminodine .....................................................................................................................................................................................
Racemethorphan ...........................................................................................................................................................................
Racemorphan ................................................................................................................................................................................
Remifentanil ...................................................................................................................................................................................
Secobarbital ...................................................................................................................................................................................
Sufentanil .......................................................................................................................................................................................
Tapentadol .....................................................................................................................................................................................
Thebaine ........................................................................................................................................................................................
2,097,255
30
30
25
30
23,010
26,500,000
770,588
30
30
30
15
25,619,700
27,673,600
150
485,020
40,000
587,229
41,800,000
15,300,000
25
25
2,584,860
22,525,461
62,000
25
22,044,741
1,000
22,500
250,000
530,837
33,010,750
519,061
54,003,559
28,204,371
516,469
30,766,670
25
35
25
8,000,000
25
5
5
3,000
172,100
4,000
13,447,541
57,137,944
List I Chemicals
lotter on DSK11XQN23PROD with NOTICES1
Ephedrine (for conversion) ............................................................................................................................................................
Ephedrine (for sale) .......................................................................................................................................................................
Phenylpropanolamine (for conversion) ..........................................................................................................................................
Phenylpropanolamine (for sale) .....................................................................................................................................................
Pseudoephedrine (for conversion) ................................................................................................................................................
Pseudoephedrine (for sale) ...........................................................................................................................................................
The Administrator also establishes
APQ for all other schedule I and II
controlled substances included in 21
CFR 1308.11 and 1308.12 at zero. In
accordance with 21 CFR 1303.13 and 21
CFR 1315.13, upon consideration of the
relevant factors, the Administrator may
adjust the 2022 APQ and AAN as
needed.
Anne Milgram,
Administrator.
[FR Doc. 2021–26227 Filed 11–29–21; 4:15 pm]
BILLING CODE 4410–09–P
100
4,136,000
14,878,320
7,990,000
1,000
174,246,000
DEPARTMENT OF JUSTICE
Notice of Lodging of Proposed
Stipulation and Settlement Under the
Comprehensive Environmental
Response, Compensation and Liability
Act
On November 15, 2021, a proposed
Stipulation Resolving the General
VerDate Sep<11>2014
16:49 Dec 01, 2021
Jkt 256001
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
E:\FR\FM\02DEN1.SGM
02DEN1
lotter on DSK11XQN23PROD with NOTICES1
68524
Federal Register / Vol. 86, No. 229 / Thursday, December 2, 2021 / Notices
Unsecured Claim of the United States
Environmental Protection Agency
(‘‘Stipulation’’) was lodged in the
United States Bankruptcy Court for the
District of Delaware in In re Exide
Holdings, Inc., et al., Case No. 20–11157
(CSS).
The proposed Stipulation resolves a
proof of claim filed by the United States,
on behalf of the Environmental
Protection Agency (EPA), against Debtor
Exide Technologies, LLC under the
Comprehensive Environmental
Response, Compensation, and Liability
Act (CERCLA) with respect to the
Portland Harbor Superfund Site
(‘‘Portland Harbor’’) in Portland,
Oregon; the Wiley’s Bridge Lead Site
(‘‘Wiley’s Bridge’’) in Reading,
Pennsylvania; the Brown’s Battery
Breaking Superfund Site (‘‘Brown’s
Battery’’) in Shoemakersville, Berks
County, Pennsylvania; and the Reading
Battery and Residential Sites
(‘‘Reading’’) in Reading, Pennsylvania.
The proposed Stipulation provides
EPA with an allowed claim of
$17,569,392.16 allocated among the
following sites: (a) $825,000 for Portland
Harbor; $4,273,189.16 for Wiley’s
Bridge; (c) $471,203 for Brown’s Battery;
and (d) $12,000,000 for Reading.
The publication of this notice opens
a period for public comment on the
Stipulation. Comments should be
addressed to the Assistant Attorney
General, Environment and Natural
Resources Division and should refer to
In re Exide Holdings, Inc., et al., D.J. Ref.
No. 90–11–2–07802/8. All comments
must be submitted no later than thirty
(30) days after the publication date of
this notice.
Comments may be submitted either by
email or by mail:
To submit comments: Send them:
By email to: pubcomment-ees.enrd@
usdoj.gov.
By mail to: Assistant Attorney
General, U.S. DOJ—ENRD, P.O., Box
7611, Washington, DC 20044–7611.
During the public comment period,
the Stipulation may be examined and
downloaded at this Justice Department
website: https://www.justice.gov/enrd/
consent-decrees. We will provide a
paper copy of the Stipulation upon
written request and payment of
reproduction costs. Please mail your
request and payment to: Consent Decree
Library, U.S. DOJ—ENRD, P.O. Box
7611, Washington, DC 20044–7611.
Please enclose a check or money order
for $2.00 (25 cents per page
VerDate Sep<11>2014
16:49 Dec 01, 2021
Jkt 256001
reproduction cost) payable to the United
States Treasury.
Jeffrey Sands,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2021–26171 Filed 12–1–21; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
[OMB Number 1105–0030]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Extension of a
Previously Approved Collection;
Comments Requested; Electronic
Applications for the Attorney General’s
Honors Program and the Summer Law
Intern Program
Office of Attorney Recruitment
and Management, Justice Management
Division, Department of Justice.
ACTION: 60-Day notice.
AGENCY:
The Department of Justice
(DOJ), Justice Management Division,
Office of Attorney Recruitment and
Management (OARM), will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
DATES: The Department of Justice
encourages public comment and will
accept input until January 31, 2022.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments,
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Deana Willis, Assistant Director, Office
of Attorney Recruitment and
Management, 450 5th Street NW, Suite
10200, Washington, DC 20530;
Deana.Willis@usdoj.gov; (202) 514–
8902.
SUMMARY:
Written
comments and/or suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the Office of Attorney
Recruitment and Management,
including whether the information will
have practical utility;
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
(2) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(3) Evaluate whether, and if so, how,
the quality, utility, and clarity of the
information to be collected can be
enhanced; and
(4) Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
Overview of This Information
Collection
1. Type of information collection:
Extension of a Currently Approved
Collection.
2. The title of the form/collection:
Electronic Applications for the Attorney
General’s Honors Program and Summer
Law Intern Program.
3. The agency form number, if any,
and the applicable component of the
department sponsoring the collection:
There is no agency form number for this
collection. The applicable component
within the Department of Justice is the
Office of Attorney Recruitment and
Management, Justice Management
Division, U.S. Department of Justice.
4. Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: Individuals or
households. Other: None. The
application form is submitted
voluntarily, once a year, by law students
and recent law school graduates (e.g.,
judicial law clerks) who will be in this
applicant pool only once.
5. An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond/reply: It is estimated that 3,500
respondents will complete the
application in approximately 1 hour per
application. It is further estimated that
it takes an average of an additional 45
minutes to review the instructions,
search existing data sources, gather the
data needed, and complete and review
the application. In addition, an
estimated 600 respondents (Honors
Program candidates selected for
interviews) will complete a Travel
Survey/Interview Scheduling form used
to schedule interviews and prepare
official travel authorizations prior to the
interviewees’ performing preemployment interview travel (as defined
by 41 CFR 301–1.3), as needed, in
approximately 10 minutes per form,
plus an estimated 400 respondents who
E:\FR\FM\02DEN1.SGM
02DEN1
]]>Agencies
[Federal Register Volume 86, Number 229 (Thursday, December 2, 2021)]
[Notices]
[Pages 68523-68524]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-26171]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Notice of Lodging of Proposed Stipulation and Settlement Under
the Comprehensive Environmental Response, Compensation and Liability
Act
On November 15, 2021, a proposed Stipulation Resolving the General
[[Page 68524]]
Unsecured Claim of the United States Environmental Protection Agency
(``Stipulation'') was lodged in the United States Bankruptcy Court for
the District of Delaware in In re Exide Holdings, Inc., et al., Case
No. 20-11157 (CSS).
The proposed Stipulation resolves a proof of claim filed by the
United States, on behalf of the Environmental Protection Agency (EPA),
against Debtor Exide Technologies, LLC under the Comprehensive
Environmental Response, Compensation, and Liability Act (CERCLA) with
respect to the Portland Harbor Superfund Site (``Portland Harbor'') in
Portland, Oregon; the Wiley's Bridge Lead Site (``Wiley's Bridge'') in
Reading, Pennsylvania; the Brown's Battery Breaking Superfund Site
(``Brown's Battery'') in Shoemakersville, Berks County, Pennsylvania;
and the Reading Battery and Residential Sites (``Reading'') in Reading,
Pennsylvania.
The proposed Stipulation provides EPA with an allowed claim of
$17,569,392.16 allocated among the following sites: (a) $825,000 for
Portland Harbor; $4,273,189.16 for Wiley's Bridge; (c) $471,203 for
Brown's Battery; and (d) $12,000,000 for Reading.
The publication of this notice opens a period for public comment on
the Stipulation. Comments should be addressed to the Assistant Attorney
General, Environment and Natural Resources Division and should refer to
In re Exide Holdings, Inc., et al., D.J. Ref. No. 90-11-2-07802/8. All
comments must be submitted no later than thirty (30) days after the
publication date of this notice.
Comments may be submitted either by email or by mail:
To submit comments: Send them:
By email to: [email protected].
By mail to: Assistant Attorney General, U.S. DOJ--ENRD, P.O., Box
7611, Washington, DC 20044-7611.
During the public comment period, the Stipulation may be examined
and downloaded at this Justice Department website: https://www.justice.gov/enrd/consent-decrees. We will provide a paper copy of
the Stipulation upon written request and payment of reproduction costs.
Please mail your request and payment to: Consent Decree Library, U.S.
DOJ--ENRD, P.O. Box 7611, Washington, DC 20044-7611.
Please enclose a check or money order for $2.00 (25 cents per page
reproduction cost) payable to the United States Treasury.
Jeffrey Sands,
Assistant Section Chief, Environmental Enforcement Section, Environment
and Natural Resources Division.
[FR Doc. 2021-26171 Filed 12-1-21; 8:45 am]
BILLING CODE P
